Navigation Links
NeoGenomics Schedules its Q4 and Full Year 2008 Earnings Release for March 5, 2009

FT. MYERS, Fla., March 3 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM) announced today that it plans to release its fourth quarter and full year 2008 financial results on Thursday March 5, 2009.

The Company has scheduled a webcast and conference call to discuss their Q4 and full year 2008 results on March 5, 2009, at 11:00 AM EST. Interested investors should dial (877) 407-8033 (domestic) and (201) 689-8033 (international) at least five minutes prior to the call. A replay of the conference call will be available until 11:59 PM on March 12, 2009 and can be accessed by dialing (877) 660-6853 (domestic) and 1(201) 612-7415 (international). The playback conference ID Number is 315878 and the PIN Number is 286. The web-cast may be accessed under the Investor Relations section of our website at or at the website of our Investor Relations firm, Hawk Associates, at or at An archive of the web-cast will be available until 11:59 PM EST on March 6, 2010.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. For additional information about NeoGenomics, visit

Interested parties can also access additional investor relations material from the American Microcap Institute at or from Hawk Associates at An investment profile about NeoGenomics may be found at

Forward Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements, Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.

SOURCE NeoGenomics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NeoGenomics to Present at the Rodman & Renshaw Healthcare Conference on November 10
2. NeoGenomics Schedules its Q2 2008 Earnings Release for July 31, 2008
3. NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008
4. NeoGenomics Files Annual Report on Form 10-KSB with the SEC
5. NeoGenomics Announces Results for the Fourth Quarter and Full Year FY 2007
6. VirtualScopics Schedules Fourth Quarter 2008 Earnings Announcement
7. Immucor Schedules Second Quarter Earnings Release and Conference Call
8. Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call
9. Accuray Reschedules Announcement of Results for First Quarter of Fiscal 2009
10. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
11. Thoratec Schedules Third Quarter 2008 Conference Call, Webcast
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
Breaking Biology Technology:
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
Breaking Biology News(10 mins):